Amphetamines and ADHD: Medical Benefits vs. Risks of Misuse

Most patients I see with stimulant problems did not start on the street. They started with a legitimate prescription, a legitimate diagnosis, and a genuine desire to function better. What shifts things is dose escalation, usually quiet and incremental, often rationalised as “it stopped working.” By the time someone reaches us, they are taking two or three times their prescribed dose, sleeping three or four hours a night, and convinced they simply have very severe ADHD. The amphetamine is no longer treating a disorder. It is driving one.

What Amphetamine Actually Does in the Brain

Amphetamine belongs to the phenethylamine class of compounds. Its mechanism is specific: it enters presynaptic nerve terminals and reverses the dopamine transporter (DAT) and norepinephrine transporter (NET), forcing these neurotransmitters out of the neuron and into the synapse regardless of whether a nerve impulse has fired. It also blocks the reuptake of both dopamine and norepinephrine, so what gets released stays in the synapse longer.

The result is a sharp increase in dopamine signalling in the striatum and prefrontal cortex, and a corresponding increase in norepinephrine signalling in the locus coeruleus. Together these effects sharpen attention, reduce impulsive responding, and improve working memory.

There is a critical distinction most people miss. In someone with ADHD, the prefrontal cortex is underactive at baseline due to reduced tonic dopamine tone. Amphetamine raises that tone toward a functional range. In someone without ADHD, the prefrontal cortex is already adequately supplied. Raising dopamine further does not improve cognition in any meaningful sustained way, and the dose required to chase that effect escalates quickly.

How Prescribed Amphetamines Differ From Street Amphetamine

Pharmaceutical amphetamines for ADHD come in several forms: mixed amphetamine salts (the combination brand most people recognise as Adderall), dextroamphetamine, and lisdexamfetamine. Lisdexamfetamine is a prodrug, meaning it is pharmacologically inert until the body cleaves the lysine molecule from it in the gut and blood. That process is slow and rate-limited, which flattens the plasma curve and reduces abuse potential considerably compared to immediate-release formulations.

Street amphetamine is typically racemic amphetamine sulfate of variable purity, often mixed with caffeine, methamphetamine precursors, or cutting agents. The distinction between amphetamine and methamphetamine matters here: methamphetamine has an additional methyl group that allows it to cross the blood-brain barrier more rapidly, producing a faster and more intense dopamine surge. You can read more about how the two compounds differ in their effects in this breakdown of amphetamine vs. methamphetamine.

The Proven Medical Benefits of Amphetamine for ADHD

The evidence base here is solid. ADHD is among the most studied psychiatric conditions in paediatric medicine, and stimulant therapy has more randomised controlled trial data behind it than almost any other psychiatric treatment for children.

A qualitative review of pharmacoepidemiology studies published in Biological Psychiatry found relative risk reductions of 9 to 58 percent for outcomes including injuries, motor vehicle accidents, educational underperformance, and substance use disorder in people taking ADHD medication versus those not on treatment. The within-individual study designs used in many of these analyses controlled for confounding by indication, which is the major methodological concern when comparing treated and untreated ADHD populations.

The finding on substance use disorder risk is counterintuitive but important. Untreated ADHD is itself a major risk factor for developing a substance use disorder, through impulsivity, sensation-seeking, and self-medication behaviour. Treating ADHD adequately appears to reduce that trajectory. The data does not suggest that giving a child amphetamines causes addiction. The risk runs the other way.

Who Gets Prescribed Amphetamines for ADHD

A diagnosis of ADHD requires a persistent pattern of inattention and/or hyperactivity-impulsivity that is present in multiple settings, began before age 12, and causes functional impairment. The DSM-5 recognises three presentations: predominantly inattentive, predominantly hyperactive-impulsive, and combined.

Global prevalence is estimated at 7.2 percent in children and adolescents and approximately 6.76 percent in adults. That is not a small population. In many countries, stimulant prescriptions are the first-line pharmacological treatment after behavioural interventions have been tried, or alongside them in moderate-to-severe cases.

In adults, the picture is more complex. Adult ADHD is underdiagnosed, and the population seeking diagnosis has expanded rapidly over the past decade. Some of that expansion reflects genuine previously unrecognised cases. Some reflects diagnostic drift and, in some settings, a pathway to obtaining amphetamines that would not otherwise be available.

The Risks of Medically Prescribed Amphetamines

Therapeutic use carries real risks even when the medication is taken exactly as prescribed.

On the cardiovascular side, amphetamines increase heart rate and blood pressure by stimulating peripheral norepinephrine release and activating alpha and beta-adrenergic receptors. At standard doses in healthy young people this is modest. In anyone with pre-existing hypertension, structural cardiac abnormalities, or arrhythmias, it is clinically relevant. Current prescribing guidelines recommend baseline cardiovascular screening before starting.

Growth suppression in children is a documented concern with long-term use, likely mediated through appetite suppression and reduced caloric intake rather than a direct hormonal mechanism. The effect appears to attenuate with age and is generally modest, but it is real and should factor into treatment decisions in prepubertal children.

Sleep disruption is almost universal. Amphetamines extend dopamine and norepinephrine availability into evening hours, delaying sleep onset. This is why afternoon and evening doses are generally avoided, and why timing of administration matters clinically.

Psychiatric adverse effects include increased anxiety, irritability, and in predisposed individuals, the potential precipitation of psychotic symptoms. The mechanism involves dopamine receptor (specifically D2) hyperstimulation in the striatum at supratherapeutic doses.

Amphetamine Misuse: What It Looks Like and Why It Happens

The 2025 Frontiers in Psychiatry systematic review of 12 studies with sample sizes up to 10,000 found a past-year misuse prevalence of 22.6 percent among people prescribed stimulants, and a diversion rate of 18.2 percent. Those numbers are not from recreational drug users. They are from people holding valid prescriptions.

Risk factors for misuse identified in the review included being prescribed an amphetamine-based stimulant specifically (as opposed to methylphenidate), comorbid depressive and anxiety symptoms, and the belief that misuse carries no real risk. Risk factors for diversion included having surplus medication and peers who were already misusing.

The pattern I see clinically is dose escalation before anything else. Patients start noticing that the afternoon dose does not seem as effective. They take an extra half tablet. Then a full one. Within months they are taking twice the prescribed amount before anyone has noticed. This happens partly because dopamine tolerance in the ventral striatum develops faster than the therapeutic effect in the prefrontal cortex, so the cognitive benefit shrinks while the urge to redose stays strong.

Non-Medical Use and the Student Population

A separate population worth naming is people who take amphetamines without any ADHD diagnosis, primarily university students using them as cognitive enhancers or for all-night study sessions. The evidence that amphetamines genuinely improve cognition in neurotypical individuals is weak. What they do reliably is increase arousal and reduce the subjective sense of fatigue, which people conflate with improved performance. Sleep deprivation impairs cognition. Amphetamine masks that impairment. The work is not better. It just feels like it is.

The Line Between Therapeutic Use and Stimulant Use Disorder

This is where clinical judgment matters most.

The DSM-5 defines stimulant use disorder along the same 11-criterion framework applied to all substance use disorders: criteria include taking more than intended, failed attempts to cut down, continued use despite harm, craving, tolerance, and withdrawal. Meeting two or more criteria over a 12-month period constitutes a diagnosis, with severity graded as mild (2-3 criteria), moderate (4-5), or severe (6 or more).

Tolerance to amphetamine develops through three mechanisms. Dopamine receptor (D2) downregulation reduces the signal per unit of drug. DAT upregulation increases reuptake, clearing dopamine faster. And presynaptic dopamine stores deplete with heavy use, leaving less available for release regardless of how much amphetamine is present.

Withdrawal from amphetamines is not medically dangerous in the way alcohol withdrawal is, but it is genuinely unpleasant. The pattern is hypersomnia, hyperphagia, profound fatigue, low mood, and anhedonia, the inability to feel pleasure. The anhedonia can last weeks. It reflects depleted dopamine tone in the reward circuitry, the same mechanism as post-cocaine crash. The stimulant comedown and what happens to the brain during it is covered in detail here.

Cardiovascular and Psychiatric Risks of Long-Term Misuse

At doses above the therapeutic range, the cardiovascular risks scale significantly. Sustained hypertension from chronic norepinephrine excess damages arterial walls. Tachycardia at rest is common. In heavy long-term users I have seen patients presenting with left ventricular hypertrophy at an age where you would not normally look for it.

Psychiatric outcomes of chronic high-dose amphetamine use include amphetamine-induced psychosis, a syndrome clinically indistinguishable from paranoid schizophrenia during the acute phase, characterised by persecutory delusions, auditory hallucinations, and disorganised thinking. It is driven by excessive D2 receptor stimulation in the mesolimbic pathway. It typically resolves with abstinence over days to weeks but can persist in heavy users, and it may unmask a pre-existing vulnerability to psychotic disorders.

Depression following stimulant cessation is neurobiological in origin. The dopamine and norepinephrine systems have been chronically supersaturated and have down-regulated in response. When the drug stops, neither system has the baseline tone to generate normal mood. This is not a personality flaw or a lack of willpower. It is pharmacology, and it resolves, though it can take weeks to months.

Amphetamine Misuse and Comorbid ADHD: A Clinically Complex Picture

This is the situation that trips up clinicians most often. A patient with genuine ADHD develops stimulant use disorder. The ADHD did not cause the addiction, but it created a neurobiological vulnerability that made it more likely. The impulsivity and novelty-seeking of ADHD are trait-level features that increase risk for all substance use disorders.

Treatment in this population needs to address both conditions simultaneously. Stopping stimulants in someone with genuine ADHD without offering an alternative treatment does not fix ADHD. Non-stimulant options including atomoxetine (a selective NET inhibitor), guanfacine, and bupropion are effective for ADHD and carry no abuse potential. They should be considered early in anyone with comorbid stimulant use disorder.

This is also where the cocaine-ADHD overlap is relevant. Many people with undiagnosed ADHD use cocaine to self-medicate the same dopamine deficit that amphetamines address therapeutically, without knowing that is what they are doing. The relationship between cocaine use and ADHD neurobiology is explored in more detail in our cocaine and ADHD article.

The DSM-5 pattern to watch for is this: you are taking more than prescribed regularly, you have tried to cut back and found you could not, your sleep is consistently less than five hours, your mood off the medication is low to the point of dysfunction, and you are spending significant time obtaining, using, or recovering from the drug. Two of those criteria, persisting for twelve months, meet the diagnostic threshold for stimulant use disorder. You do not need to be injecting methamphetamine in an alley to qualify. A professional taking double their prescribed Adderall every day for a year qualifies.

At Phuket Island Rehab, we treat stimulant use disorder as a medical and psychological condition with a structured clinical programme that includes medically supervised withdrawal, psychiatric evaluation for comorbid ADHD, and evidence-based therapies including cognitive-behavioural therapy. We work with patients from across Asia and internationally who need a confidential, professional residential setting away from their usual environment.

Amphetamine is a stimulant prescribed for ADHD because it corrects a specific dopamine and norepinephrine deficit in the prefrontal cortex. At therapeutic doses, with proper diagnosis, it reduces accident risk, improves academic and occupational function, and appears to lower the long-term risk of substance use disorder compared to untreated ADHD. The risks at therapeutic doses are real but manageable: cardiovascular monitoring, sleep management, and regular psychiatric review are standard of care. The risks of misuse are categorically different. Chronic supratherapeutic use drives dopamine receptor downregulation, cardiovascular strain, psychiatric instability including amphetamine-induced psychosis, and stimulant use disorder meeting DSM-5 criteria. Pharmacoepidemiology data now puts past-year misuse rates above 22 percent in prescribed populations, which means clinicians prescribing these medications cannot assume safe use without active monitoring.

For patients and families navigating this, the practical distinction is dose. Therapeutic amphetamine use holds dose stable over time. Misuse escalates. If the dose that worked three months ago does not work now and the impulse is to take more rather than to reassess the diagnosis, that is the clinical signal. Stimulant use disorder is treatable. The dopaminergic deficit it produces is time-limited with abstinence. Full recovery of reward circuitry function is achievable, typically within twelve months for moderate users. As John A. Smith of Phuket Island Rehab puts it: “The patients I worry about are not the ones who admit they have a problem. They are the ones who are certain they are just treating their ADHD, while taking three times what any prescription would say.”

Is amphetamine safe for long-term ADHD treatment?

Amphetamine is generally safe for long-term ADHD treatment at therapeutic doses with appropriate monitoring, but it is not risk-free. The main long-term concerns are cardiovascular effects from sustained norepinephrine stimulation, modest growth suppression in children, and psychiatric adverse effects in people with predisposing conditions. The pharmacoepidemiology data shows that for most patients with genuine ADHD, the benefits of treatment outweigh these risks. What matters is regular review of dose, blood pressure, sleep, and mood, and a willingness to switch to non-stimulant alternatives if misuse patterns emerge.

Can you become addicted to prescription amphetamines?

Yes. Stimulant use disorder meeting DSM-5 criteria can develop from prescription amphetamine use, particularly with dose escalation. The risk is higher with immediate-release formulations than with prodrug formulations like lisdexamfetamine, because the rate of dopamine increase in the nucleus accumbens is a key driver of addiction potential. A 2025 systematic review found that 22.6 percent of people prescribed stimulants reported misuse in the past year. Comorbid depression, anxiety, and the belief that prescription drugs cannot be addictive are specific risk factors.

What is the difference between amphetamine and methamphetamine?

Amphetamine and methamphetamine share the same basic phenethylamine structure, but methamphetamine has an additional methyl group that allows it to cross the blood-brain barrier significantly faster. This produces a more rapid and intense dopamine surge, which is why methamphetamine has substantially higher addiction potential and more severe neurotoxic effects with chronic use. Pharmaceutical amphetamines prescribed for ADHD are a controlled but structurally distinct class. At equivalent doses, methamphetamine delivers more drug to the brain, faster, which is the pharmacological basis for the difference in abuse liability.

What happens to the brain when you stop taking amphetamines?

Stopping amphetamines after regular use triggers a withdrawal syndrome driven by dopamine and norepinephrine depletion. The acute phase involves hypersomnia, intense fatigue, increased appetite, low mood, and anhedonia (inability to feel pleasure). This typically peaks in the first 48 to 72 hours and improves over one to three weeks for moderate users. In heavy or long-term users, anhedonia and depressive symptoms can persist for weeks to months, reflecting D2 receptor downregulation that takes time to reverse. This is neurobiological, not psychological weakness, and it resolves with time.

Does treating ADHD with amphetamines increase the risk of drug addiction later?

The evidence points in the opposite direction. Untreated ADHD increases the risk of developing a substance use disorder, through impulsivity, sensation-seeking, and self-medication. Adequate pharmacological treatment of ADHD appears to reduce that risk. Pharmacoepidemiology studies show relative risk reductions for substance use disorder outcomes in treated versus untreated ADHD populations. The concern about stimulant treatment creating addiction has been studied extensively and is not supported by the current evidence for patients with genuine ADHD diagnoses taking therapeutic doses.

What are the signs that stimulant use has crossed into misuse?

The clearest clinical signs are dose escalation beyond what is prescribed, taking the medication more frequently than directed, obtaining it from sources other than your prescribing doctor, using it to manage mood rather than attention, and significant sleep disruption. Functionally, the shift looks like taking an extra dose because the prescribed dose “stopped working,” being unable to function on days without the medication, and continuing to use it despite visible effects on sleep, mood, or relationships. These map directly onto DSM-5 stimulant use disorder criteria.